Aeglea Bio Therapeutics Inc to Present New 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 SSIEM Symposium - Conference Call Transcript
Greetings, and welcome to the Aeglea BioTherapeutics Clinical Update. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the conference over to your host, Mr. David Calusdian with Sharon Merrill Associates. Thank you. You may begin.
Good morning, and welcome to Aeglea BioTherapeutics Clinical Update Conference Call. After management's prepared remarks, they will be available to take your questions.
Before we begin, please note that today's call may include a number of forward-looking statements, including comments on the company's business strategy; strengths and priorities; the timing, plans and success of clinical trials and related data; the timing of announcements and updates relating to clinical trials and related data; the safety, therapeutic benefits and economic value of product candidates; the advancement of technologies and proprietary product candidates; regulatory pathways for development programs; the success of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
